CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.20M | 2.79M | 2.63M | 2.85M | 2.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.11M | 2.10M | 4.40M | 5.15M | 4.55M |
| Operating Income | -5.11M | -2.10M | -4.40M | -5.15M | -4.55M |
| Income Before Tax | -5.11M | 671.90K | -4.23M | -2.45M | -2.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.11M | 671.90K | -4.23M | -2.45M | -2.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.11M | 671.90K | -4.23M | -2.45M | -2.30M |
| EBIT | -5.11M | -2.10M | -4.40M | -5.15M | -4.55M |
| EBITDA | -5.03M | -2.00M | -4.29M | -5.03M | -4.44M |
| EPS Basic | -33.42 | -35.71 | -178.73 | -63.78 | -63.78 |
| Normalized Basic EPS | -19.55 | -28.17 | -111.71 | -- | -42.32 |
| EPS Diluted | -33.42 | -35.71 | -178.73 | -63.78 | -63.78 |
| Normalized Diluted EPS | -19.55 | -28.17 | -111.71 | -- | -42.32 |
| Average Basic Shares Outstanding | 3.60M | 1.30M | 521.60K | -- | 37.90K |
| Average Diluted Shares Outstanding | 3.60M | 1.30M | 521.60K | 37.90K | 37.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |